4-Aminopiperidine derivatives

• US 20060135561A1
• Filed: 12/14/2005
• Published: 06/22/2006
• Est. Priority Date: 12/20/2004
• Status: Active Grant

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Kuhn, Bernd, Luebbers, Thomas, Hunziker, Daniel, Ricklin, Fabienne, Loeffler, Bernd Michael, Boehringer, Markus
• Granted Patent: US 7,683,079 B2
• Time in Patent Office: Days
• US Class Current: 514/317
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07D 211/58 attached in position 4
• CPC Class Codes: C07D 211/60 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 277/04 having no double bonds between ring members or between ring members and non-ring members

Abstract

The present invention relates to compounds of the formula (I)
wherein R¹ and R² are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or β-cell protection.

Claims

7-1. The compound according to claim 1, wherein R² is

n-butyl.

14-2. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier and/or adjuvant.